These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36816979)

  • 21. Apatinib inhibits tumor growth and angiogenesis in PNET models.
    Wu S; Zhou J; Guo J; Hua Z; Li J; Wang Z
    Endocr Connect; 2019 Jan; 8(1):8-19. PubMed ID: 30557852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer.
    Zhao S; Ren S; Jiang T; Zhu B; Li X; Zhao C; Jia Y; Shi J; Zhang L; Liu X; Qiao M; Chen X; Su C; Yu H; Zhou C; Zhang J; Camidge DR; Hirsch FR
    Cancer Immunol Res; 2019 Apr; 7(4):630-643. PubMed ID: 30755403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-angiogenic therapies for advanced esophago-gastric cancer.
    Fontana E; Sclafani F; Cunningham D
    Indian J Med Paediatr Oncol; 2014 Oct; 35(4):253-62. PubMed ID: 25538401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical advances in the development of novel VEGFR2 inhibitors.
    Fontanella C; Ongaro E; Bolzonello S; Guardascione M; Fasola G; Aprile G
    Ann Transl Med; 2014 Dec; 2(12):123. PubMed ID: 25568876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models.
    Wang Q; Gao J; Di W; Wu X
    Cancer Immunol Immunother; 2020 Sep; 69(9):1781-1799. PubMed ID: 32347357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Latest Results for Anti-Angiogenic Drugs in Cancer Treatment.
    Frandsen S; Kopp S; Wehland M; Pietsch J; Infanger M; Grimm D
    Curr Pharm Des; 2016; 22(39):5927-5942. PubMed ID: 27426129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.
    Chuai Y; Rizzuto I; Zhang X; Li Y; Dai G; Otter SJ; Bharathan R; Stewart A; Wang A
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013348. PubMed ID: 33661538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade.
    Osta BE; Carlisle J; Steuer C; Pakkala S; Leal T; Dhodapkar M; Liu Y; Chen Z; Owonikoko T; Ramalingam S
    Clin Lung Cancer; 2022 Nov; 23(7):e400-e404. PubMed ID: 35863963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apatinib exhibits anti-leukemia activity in preclinical models of acute lymphoblastic leukemia.
    Deng M; Zha J; Jiang Z; Jia X; Shi Y; Li P; Chen XL; Fang Z; Du Z; Xu B
    J Transl Med; 2018 Feb; 16(1):47. PubMed ID: 29490645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apatinib for metastatic breast cancer in non-clinical trial setting: Satisfying efficacy regardless of previous anti-angiogenic treatment.
    Lin Y; Wu Z; Zhang J; Hu X; Wang Z; Wang B; Cao J; Wang L
    Tumour Biol; 2017 Jun; 39(6):1010428317711033. PubMed ID: 28639910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies.
    Aprile G; Ferrari L; Cremolini C; Bergamo F; Fontanella C; Battaglin F; Rihawi K; Lonardi S; Loupakis F; Scartozzi M
    Expert Rev Clin Pharmacol; 2016 Jul; 9(7):877-85. PubMed ID: 27149032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Significant response to ramucirumab monotherapy in chemotherapy-resistant recurrent alpha-fetoprotein-producing gastric cancer: A case report.
    Arakawa Y; Tamura M; Aiba K; Morikawa K; Aizawa D; Ikegami M; Yuda M; Nishikawa K
    Oncol Lett; 2017 Sep; 14(3):3039-3042. PubMed ID: 28928842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of apatinib treatment for gastric cancer, hepatocellular carcinoma and non-small cell lung cancer: a meta-analysis.
    Xue JM; Astère M; Zhong MX; Lin H; Shen J; Zhu YX
    Onco Targets Ther; 2018; 11():6119-6128. PubMed ID: 30288047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apatinib-loaded nanoparticles suppress vascular endothelial growth factor-induced angiogenesis and experimental corneal neovascularization.
    Lee JE; Kim KL; Kim D; Yeo Y; Han H; Kim MG; Kim SH; Kim H; Jeong JH; Suh W
    Int J Nanomedicine; 2017; 12():4813-4822. PubMed ID: 28740387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-Colorectal Cancer Effect via Application of Polyethylene Glycol Modified Liposomal Apatinib.
    Hu Y; Zhou P; Lin Y; Yang D; Wang B
    J Biomed Nanotechnol; 2019 Jun; 15(6):1256-1266. PubMed ID: 31072433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bevacizumab combined with apatinib enhances antitumor and anti-angiogenesis effects in a lung cancer model
    Wang M; Zeng Q; Li Y; Imani S; Xie D; Li Y; Han Y; Fan J
    J Drug Target; 2020 Nov; 28(9):961-969. PubMed ID: 32374627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apatinib exhibits cytotoxicity toward leukemia cells by targeting VEGFR2-mediated prosurvival signaling and angiogenesis.
    Deng M; Zha J; Zhao H; Jia X; Shi Y; Li Z; Fu G; Yu L; Fang Z; Xu B
    Exp Cell Res; 2020 May; 390(1):111934. PubMed ID: 32126236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. VEGF-Independent Angiogenic Factors: Beyond VEGF/VEGFR2 Signaling.
    Eguchi R; Kawabe JI; Wakabayashi I
    J Vasc Res; 2022; 59(2):78-89. PubMed ID: 35152220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted inhibition of VEGF receptor 2: an update on ramucirumab.
    Clarke JM; Hurwitz HI
    Expert Opin Biol Ther; 2013 Aug; 13(8):1187-96. PubMed ID: 23803182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives.
    Calvetti L; Pilotto S; Carbognin L; Ferrara R; Caccese M; Tortora G; Bria E
    Expert Opin Biol Ther; 2015; 15(9):1359-70. PubMed ID: 26190526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.